Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.

Liver cancer·2026

Same author

Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Journal of gastroenterology and hepatology·2026

Same author

Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

Hepatology (Baltimore, Md.)·2026

Same author

Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

Hepatology research : the official journal of the Japan Society of Hepatology·2026

Same author

Association of Liver Immune Status Index With the Nutritional Status and Prognosis in Patients With Cirrhosis.

In vivo (Athens, Greece)·2026

Search research articles

Related Experiment Video

Updated: Feb 6, 2026

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Published on: March 12, 2015

[PEG-IFN/IFN monotherapy].

Hirayuki Enomoto, Shuhei Nishiguchi

Nihon Rinsho. Japanese Journal of Clinical Medicine

|March 14, 2015

Summary

Pegylated-interferon (PEG-IFN) monotherapy effectively eradicates Hepatitis C Virus (HCV) in patients with rapid viral response, reducing side effects. Low-dose interferon may inhibit liver cancer development, but benefits and risks require careful evaluation.

Area of Science:

Hepatology
Virology
Oncology

Background:

Chronic hepatitis C (HCV) infection poses risks for liver disease and cancer.
Pegylated-interferon (PEG-IFN) and interferon therapies have been used for HCV treatment.
These therapies aim for viral eradication and prevention of liver cancer (hepatocarcinogenesis).

Purpose of the Study:

To evaluate the efficacy of PEG-IFN monotherapy for HCV eradication.
To assess the potential of low-dose interferon in inhibiting hepatocarcinogenesis.
To analyze the benefits and adverse events associated with interferon therapy.

Main Methods:

Analysis of patients receiving PEG-IFN monotherapy.
Assessment of viral response and eradication rates.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Electrophysiology of Scorpion Peg Sensilla

Electrophysiology of Scorpion Peg Sensilla

Published on: April 13, 2011

Related Experiment Videos

Last Updated: Feb 6, 2026

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Published on: March 12, 2015

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Electrophysiology of Scorpion Peg Sensilla

Electrophysiology of Scorpion Peg Sensilla

Published on: April 13, 2011

Monitoring of liver function markers (ALT) and tumor markers (AFP) for cancer inhibition.

Main Results:

PEG-IFN monotherapy demonstrated efficient HCV eradication in patients with rapid viral response.
Reduced side effects were observed in patients achieving rapid viral response.
Low-dose interferon showed potential for inhibiting hepatocarcinogenesis in select patients with reduced ALT or AFP.

Conclusions:

PEG-IFN monotherapy is effective for HCV eradication with favorable outcomes in rapid responders.
Low-dose interferon may offer a strategy for hepatocarcinogenesis inhibition, warranting further investigation.
Careful consideration of benefits versus adverse events is crucial for interferon therapy decisions.